WO2012019426A8 - 酞嗪酮类衍生物、其制备方法及其在医药上的应用 - Google Patents

酞嗪酮类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
WO2012019426A8
WO2012019426A8 PCT/CN2011/001222 CN2011001222W WO2012019426A8 WO 2012019426 A8 WO2012019426 A8 WO 2012019426A8 CN 2011001222 W CN2011001222 W CN 2011001222W WO 2012019426 A8 WO2012019426 A8 WO 2012019426A8
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pharmaceutical use
phthalazinone derivative
derivative
phthalazinone
Prior art date
Application number
PCT/CN2011/001222
Other languages
English (en)
French (fr)
Other versions
WO2012019426A1 (zh
Inventor
邓炳初
李心
王斌
李相勤
陈阳
陈雪江
张蕾
宋敏
Original Assignee
上海恒瑞医药有限公司
江苏恒瑞医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海恒瑞医药有限公司, 江苏恒瑞医药股份有限公司 filed Critical 上海恒瑞医药有限公司
Priority to CN2011800046090A priority Critical patent/CN102666539A/zh
Priority to TW100141565A priority patent/TW201305181A/zh
Publication of WO2012019426A1 publication Critical patent/WO2012019426A1/zh
Publication of WO2012019426A8 publication Critical patent/WO2012019426A8/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/CN2011/001222 2010-08-09 2011-07-26 酞嗪酮类衍生物、其制备方法及其在医药上的应用 WO2012019426A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2011800046090A CN102666539A (zh) 2010-08-09 2011-07-26 酞嗪酮类衍生物、其制备方法及其在医药上的应用
TW100141565A TW201305181A (zh) 2011-07-26 2011-11-15 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010102483179A CN102372706A (zh) 2010-08-09 2010-08-09 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN201010248317.9 2010-08-09

Publications (2)

Publication Number Publication Date
WO2012019426A1 WO2012019426A1 (zh) 2012-02-16
WO2012019426A8 true WO2012019426A8 (zh) 2012-05-10

Family

ID=45567314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/001222 WO2012019426A1 (zh) 2010-08-09 2011-07-26 酞嗪酮类衍生物、其制备方法及其在医药上的应用

Country Status (2)

Country Link
CN (2) CN102372706A (zh)
WO (1) WO2012019426A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574197A (zh) * 2020-12-07 2021-03-30 泰安汉威集团有限公司 一种化合物c的手性纯化方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103570722A (zh) * 2012-07-19 2014-02-12 中国科学院上海药物研究所 稠环哒嗪酮类化合物及其制备方法和用途
CN103570730A (zh) * 2012-08-01 2014-02-12 中国科学院上海药物研究所 具有桥环结构的稠环哒嗪酮类化合物及其制备方法和用途
CN103833756B (zh) * 2012-11-26 2016-12-21 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和用途
GEP201706691B (en) * 2012-12-31 2017-06-26 Cadila Healthcare Ltd Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
CA2935811C (en) 2014-03-07 2018-09-18 F. Hoffmann-La Roche Ag 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN105503890A (zh) * 2014-09-23 2016-04-20 天津药明康德新药开发有限公司 一种5-叔丁氧羰基八氢呋喃[3,2-c]并吡啶-7-羧酸的合成方法
PT3270915T (pt) 2015-03-16 2020-06-17 H Hoffnabb La Roche Ag Tratamento combinado com um agonista do tlr7 e um inibidor da montagem da cápside do vhb
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
WO2017071636A1 (zh) * 2015-10-30 2017-05-04 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
CN107207504B (zh) * 2015-12-16 2020-03-10 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
AU2017280334C1 (en) 2016-06-24 2022-10-20 AtlasMedx, Inc Phthalazine derivatives as inhibitors of PARP1, PARP2 and/or tubulin useful for the treatment of cancer
ES2894605T3 (es) 2016-09-13 2022-02-15 Hoffmann La Roche Tratamiento combinado con un agonista de TLR7 y un inhibidor del ensamblaje de la cápside del VHB
MD3483164T2 (ro) 2017-03-20 2020-07-31 Forma Therapeutics Inc Compoziții pirolopirolice ca activatori ai piruvat kinazei (PKR)
CN107200744A (zh) * 2017-05-31 2017-09-26 湖南华腾制药有限公司 一种制备吡咯并嘧啶盐酸盐的方法
CN109251204A (zh) * 2017-07-13 2019-01-22 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
EP3674304B1 (en) * 2017-08-24 2022-04-13 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of parp-1 inhibitor and preparation method therefor
CN109867667B (zh) * 2017-12-05 2021-06-11 中国药科大学 含有吡啶并嘧啶结构的parp和pi3k双靶点抑制剂
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
CN109748923A (zh) * 2019-01-31 2019-05-14 中国药科大学 含苯并[4,5]咪唑[1,2-a]吡嗪酮类衍生物及其制备方法与用途
CN111620866A (zh) * 2019-02-27 2020-09-04 南京药石科技股份有限公司 一种顺式-7,7-二氟-六氢-1H 吡咯并[3,4-c]吡啶衍生物及其制备方法
CN113614088A (zh) 2019-03-25 2021-11-05 豪夫迈·罗氏有限公司 Hbv核心蛋白变构修饰剂化合物的固体形式
CA3176219A1 (en) 2020-04-21 2021-10-28 Kunhee LEE Crystalline forms of phthalazinone compound
US12060345B2 (en) 2020-04-21 2024-08-13 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
TW202313040A (zh) * 2021-06-02 2023-04-01 南韓商愛迪恩斯股份有限公司 以酞嗪酮衍生物治療病症的方法
IL313904A (en) 2022-01-11 2024-08-01 Suven Life Sciences Ltd Heterocyclic derivatives and their use in the treatment of central nervous system disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CN1905864B (zh) * 2003-12-01 2011-04-06 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
UY31603A1 (es) * 2008-01-23 2009-08-31 Derivados de ftalazinona

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574197A (zh) * 2020-12-07 2021-03-30 泰安汉威集团有限公司 一种化合物c的手性纯化方法
CN112574197B (zh) * 2020-12-07 2021-12-31 泰安汉威集团有限公司 一种化合物c的手性纯化方法

Also Published As

Publication number Publication date
CN102666539A (zh) 2012-09-12
CN102372706A (zh) 2012-03-14
WO2012019426A1 (zh) 2012-02-16

Similar Documents

Publication Publication Date Title
WO2012019426A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2012019430A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2012019427A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
WO2009156462A3 (en) Organic compounds
MX358679B (es) Derivado de anillo de heteroarilo de seis miembros de pirrol, método de preparación del mismo y usos médicos del mismo.
WO2012065019A3 (en) Combination comprising pyridopyrimidinone inhibitors of pi3k alpha
WO2007149907A3 (en) Pyrazoloquinazolinones as parp inhibitors
CA2873723A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
WO2010128050A3 (en) Dihydroorotate - dehydrogenasee inhibitors as virostatic compounds
WO2011143772A9 (en) Inhibitors of hiv replication
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2009013545A3 (en) Chemical compounds
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2012118308A3 (ko) 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물.
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2014036502A8 (en) Tetracycline compounds
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2012140596A8 (en) Glycoside derivatives and uses thereof
WO2009094457A3 (en) Substituted benzhydrylethers
WO2011088160A3 (en) Novel cyp17 inhibitors
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
WO2010121675A3 (en) Thiazolyl-benzimidazoles

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180004609.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815985

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11815985

Country of ref document: EP

Kind code of ref document: A1